Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtaiBeckley Inc. (NASDAQ: ATAI) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. AtaiBeckley, a clinical-stage biopharmaceutical and biotechnology company focused on mental health treatments, uses SEC reports to disclose material events, financing activities, corporate transactions and updates related to its clinical pipeline.
Investors researching ATAI can review current and historical filings such as Form 8-K reports that describe significant developments. Recent 8-K filings have addressed topics including the completion of the acquisition of Beckley Psytech Limited and the resulting name change to Atai Beckley N.V., public offerings of common shares to fund clinical programs, FDA Breakthrough Therapy designation for BPL-003 in treatment-resistant depression, and the redomiciliation process that led to AtaiBeckley Inc. becoming a Delaware corporation. Other filings detail shareholder votes on the Beckley Psytech transaction and redomiciliation, as well as prospectus supplements related to registered offerings and resales.
Through this page, users can also locate references to AtaiBeckley’s financial reporting, such as earnings press releases furnished on Form 8-K, and legal or transactional documents filed as exhibits, including share purchase agreements and underwriting agreements. These materials help explain how AtaiBeckley finances the development of its key programs BPL-003, VLS-01 and EMP-01 and how it structures its corporate operations.
Stock Titan enhances the ATAI filings page with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure new AtaiBeckley filings appear promptly, while dedicated sections make it easier to find items such as current reports, registration statements and, when available, insider transaction reports on Form 4. This combination of raw filings and AI-generated insights can support deeper due diligence on AtaiBeckley’s regulatory and financial disclosures.
ATAI Life Sciences closed a public offering of 27,283,750 common shares at $5.48 per share, including the underwriters’ option exercised in full for 3,558,750 additional shares. The company said the offering has closed.
ATAI plans to use net proceeds, together with existing cash and investments, to advance its pipeline: funding the planned Phase 3 program for BPL-003 (mebufotenin benzoate) nasal spray through the first Phase 3 top-line readout, completing the Phase 2 trial of VLS-01 (buccal film DMT), and completing the Phase 2a study for EMP-01 (oral R-MDMA), as well as for working capital and general corporate purposes. Based on its plan, ATAI estimates liquidity will fund operations into 2029.
ATAI Life Sciences priced a public offering of 23,725,000 common shares at $5.48 per share under its automatic shelf on Form S-3, with Jefferies as representative of the underwriters. The company granted a 30-day option to purchase up to an additional 3,558,750 shares, and expects closing on or about October 20, 2025, subject to customary conditions.
ATAI estimates net proceeds of approximately $121.2 million, or $139.4 million if the option is exercised in full. The company plans to use the proceeds, together with existing cash and investments, to advance clinical programs and for working capital and general corporate purposes. Management estimates cash, cash equivalents and short-term investments were approximately $114.6 million as of September 30, 2025, and that available capital is sufficient to fund operating expenses into 2028, though additional funds may be needed to complete the Phase 3 study of BPL-003.
ATAI Life Sciences N.V. is offering 23,725,000 common shares at $5.48 per share, a primary raise totaling $130,013,000 in gross proceeds. Underwriting discounts are $0.349876 per share, for $121,712,191.90 in proceeds before expenses; the company estimates net proceeds of about $121.2 million. The underwriters have a 30‑day option to buy up to 3,558,750 additional shares.
ATAI intends to use proceeds to advance clinical development, and for working capital and general corporate purposes. Shares outstanding will be 235,969,597 after the offering (or 239,528,347 if the option is exercised), versus 212,244,597 outstanding as of June 30, 2025. ATAI preliminarily expects $114.6 million in cash, cash equivalents and short‑term investments as of September 30, 2025. Recent items include an agreement to issue 105,044,902 shares for the planned Beckley Psytech combination (subject to shareholder approval) and FDA Breakthrough Therapy designation for Beckley Psytech’s BPL‑003.
atai Life Sciences (ATAI) reported that the U.S. FDA granted Breakthrough Therapy designation to BPL-003 (intranasal mebufotenin benzoate) for adult patients with treatment-resistant depression. The designation is reserved for drugs addressing serious conditions where early clinical evidence indicates substantial improvement over existing therapies.
The announcement highlights positive topline results from Beckley Psytech’s Phase 2b blinded study: a single 8 mg or 12 mg dose produced clinically meaningful and statistically significant reductions in depressive symptoms within 24 hours, with effects sustained through the eight-week trial. Most patients were assessed as ready for discharge at 90 minutes post-dose, aligning with an in-clinic, two-hour treatment paradigm.
The communication also references a contemplated acquisition of Beckley Psytech and directs investors to the company’s proxy materials for details.
atai Life Sciences (ATAI) reported that the U.S. FDA granted Breakthrough Therapy designation to BPL-003 (intranasal mebufotenin benzoate) for adult patients with treatment-resistant depression. The designation is reserved for drugs addressing serious conditions where early clinical evidence indicates substantial improvement over existing therapies.
The announcement highlights positive topline results from Beckley Psytech’s Phase 2b blinded study: a single 8 mg or 12 mg dose produced clinically meaningful and statistically significant reductions in depressive symptoms within 24 hours, with effects sustained through the eight-week trial. Most patients were assessed as ready for discharge at 90 minutes post-dose, aligning with an in-clinic, two-hour treatment paradigm.
The communication also references a contemplated acquisition of Beckley Psytech and directs investors to the company’s proxy materials for details.
atai Life Sciences (ATAI) reported that the U.S. FDA granted Breakthrough Therapy designation to BPL-003 (intranasal mebufotenin benzoate) for adult patients with treatment-resistant depression. The designation is reserved for drugs addressing serious conditions where early clinical evidence indicates substantial improvement over existing therapies.
The announcement highlights positive topline results from Beckley Psytech’s Phase 2b blinded study: a single 8 mg or 12 mg dose produced clinically meaningful and statistically significant reductions in depressive symptoms within 24 hours, with effects sustained through the eight-week trial. Most patients were assessed as ready for discharge at 90 minutes post-dose, aligning with an in-clinic, two-hour treatment paradigm.
The communication also references a contemplated acquisition of Beckley Psytech and directs investors to the company’s proxy materials for details.
ATAI Life Sciences launched a preliminary prospectus supplement for a public offering of common shares. The deal includes a 30‑day option for underwriters to buy additional shares after pricing. Proceeds will go to ATAI and are intended to advance clinical development, with the remainder for working capital and general corporate purposes.
ATAI reported preliminary cash, cash equivalents and short‑term investments of $114.6 million as of September 30, 2025. Recent updates include a planned strategic combination with Beckley Psytech, to be completed subject to shareholder approval, for which ATAI agreed to issue 105,044,902 shares. Beckley Psytech’s BPL‑003 received FDA Breakthrough Therapy designation for treatment‑resistant depression based on positive Phase 2b results. ATAI also plans a redomiciliation to Delaware via a Luxembourg merger structure, subject to approvals. Shares trade on Nasdaq as ATAI; the last reported price was $5.96 on October 15, 2025.
ATAI Life Sciences launched a preliminary prospectus supplement for a public offering of common shares. The deal includes a 30‑day option for underwriters to buy additional shares after pricing. Proceeds will go to ATAI and are intended to advance clinical development, with the remainder for working capital and general corporate purposes.
ATAI reported preliminary cash, cash equivalents and short‑term investments of $114.6 million as of September 30, 2025. Recent updates include a planned strategic combination with Beckley Psytech, to be completed subject to shareholder approval, for which ATAI agreed to issue 105,044,902 shares. Beckley Psytech’s BPL‑003 received FDA Breakthrough Therapy designation for treatment‑resistant depression based on positive Phase 2b results. ATAI also plans a redomiciliation to Delaware via a Luxembourg merger structure, subject to approvals. Shares trade on Nasdaq as ATAI; the last reported price was $5.96 on October 15, 2025.
ATAI Life Sciences launched a preliminary prospectus supplement for a public offering of common shares. The deal includes a 30‑day option for underwriters to buy additional shares after pricing. Proceeds will go to ATAI and are intended to advance clinical development, with the remainder for working capital and general corporate purposes.
ATAI reported preliminary cash, cash equivalents and short‑term investments of $114.6 million as of September 30, 2025. Recent updates include a planned strategic combination with Beckley Psytech, to be completed subject to shareholder approval, for which ATAI agreed to issue 105,044,902 shares. Beckley Psytech’s BPL‑003 received FDA Breakthrough Therapy designation for treatment‑resistant depression based on positive Phase 2b results. ATAI also plans a redomiciliation to Delaware via a Luxembourg merger structure, subject to approvals. Shares trade on Nasdaq as ATAI; the last reported price was $5.96 on October 15, 2025.
ATAI Life Sciences N.V. filed a report providing additional information on its planned acquisition of Beckley Psytech Limited, a U.K.-based company in which it already holds a stake. The filing links to unaudited interim condensed consolidated financial statements for Beckley Psytech as of June 30, 2025 and for the six-month periods ended June 30, 2025 and 2024, which are included as an exhibit.
The transaction would give ATAI the entire issued share capital of Beckley Psytech that it does not already own, under a share purchase agreement signed on June 2, 2025. Closing is currently expected in the fourth quarter of 2025, subject to ATAI shareholder approval and other customary conditions, and the company cautions there is no assurance the deal will be completed on this timeline or at all.
ATAI Life Sciences N.V. reporting person Ryan Barrett (Chief Legal and Business Officer) was granted 175,000 stock options on 10/01/2025. The options have an exercise price of $5.20 and an expiration date of 10/01/2035. The award vests 25% after one year, with the remainder vesting in 36 substantially equal monthly installments thereafter. The Form 4 was signed on 10/03/2025.
Ryan Barrett, identified as a Director and as the company’s Chief Legal and Business Officer in the remarks, filed an initial Form 3 for ATAI Life Sciences N.V. (ATAI) reporting direct ownership of 155,066 common shares and multiple fully or partially vested stock options. The filing lists nine option grants covering 347,000 to 757,915 underlying shares with exercise prices ranging from $1.18 to $15.00 and various exercisable/expiration dates through 03/03/2035.
Apeiron Investment Group Ltd. and related reporting person Christian Angermayer disclosed insider transactions in ATAI Life Sciences N.V. (ATAI). On 09/30/2025 Apeiron converted convertible notes into 2,367,200 common shares, increasing its reported beneficial ownership to 53,412,414 shares. The conversion price for the Convertible Notes is EUR 17.00 per note. The filing also shows 147,950 convertible notes with underlying common shares noted as part of the transaction. Angermayer is identified as a director and a >10% owner. The Form 4 reports the transactions as acquisitions by conversion of debt instruments into equity.
ATAI Life Sciences N.V. files an S-3ASR prospectus dated September 29, 2025 registering securities for resale. Its common shares trade on the Nasdaq Global Market under ATAI, with a reported last sale price of $5.27 on September 26, 2025. The prospectus incorporates by reference the 2024 Form 10-K and subsequent 2025 10-Qs and 8-Ks (dates listed), and describes shareholder rights including one vote per ordinary share and registered-share form. The filing details corporate governance items: director appointment process, voting quorums, a federal forum provision for U.S. Securities Act claims, director indemnification subject to exceptions, and director liability under Dutch law. It also describes potential offerings of debt securities, events of default, modification and waiver mechanics under an indenture, DTC/book-entry mechanics, and auditors' reports by Deloitte & Touche LLP and PwC (Beckley Psytech financials include a going-concern explanatory paragraph).